Get started
Author

Tatiana Viktorovna Kudling

Observed names: Kudling, Tatiana, T. Kudling, T. V. Kudling, Tatiana Kudling, Tatiana V Kudling, Tatiana V. Kudling
ORCID: 0000-0003-4481-1617
Observed ORCID: 0000-0003-4481-1617
OpenAlex ID: A5027603010
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
2022 · James H. A. Clubb, Tatiana V. Kudling, et al. · Frontiers in Immunology · 49
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
2025 · Matthew Stephen Block, James Hugo Armstrong Clubb, et al. · Nature Communications · 39
PDF
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
2021 · Dafne C. A. Quixabeira, Sadia Zafar, et al. · Frontiers in Immunology · 37
PDF
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 36
PDF
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
2022 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 36
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors
2024 · Elise Jirovec, Dafne C. A. Quixabeira, et al. · Journal of Experimental & Clinical Cancer Research · 28
PDF
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
2023 · Tatiana V. Kudling, James H.A. Clubb, et al. · OncoImmunology · 25
PDF
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 23
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
2020 · Sadia Zafar, Dafne Carolina Alves Quixabeira, et al. · Cancer Gene Therapy · 22
PDF
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma
2025 · Tine J. Monberg, Santeri A. Pakola, et al. · Cell Reports Medicine · 21
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
2022 · Dafne C. A. Quixabeira, Victor Cervera-Carrascon, et al. · OncoImmunology · 18
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
2022 · Camilla Heiniö, James Clubb, et al. · Diseases · 16
PDF
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
2022 · Saru Basnet, Joao M. Santos, et al. · Molecular Therapy — Oncolytics · 14
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
2023 · D. C. A. Quixabeira, S. Pakola, et al. · Cancer Gene Therapy · 12
PDF
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
2023 · D. C. A. Quixabeira, E. Jirovec, et al. · Cancer Gene Therapy · 12
PDF
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
2023 · James H. A. Clubb, Tatiana V. Kudling, et al. · Frontiers in Immunology · 12
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
2025 · Santeri A Pakola, James H A Clubb, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Crystal structures of CDC21-1 inteins from hyperthermophilic archaea reveal the selection mechanism for the highly conserved homing endonuclease insertion site
2019 · Hannes M. Beyer, Kornelia M. Mikula, et al. · Extremophiles · 9
PDF
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
2024 · T.J. Monberg, T. Kudling, et al. · Immuno-Oncology Technology · 8
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
2023 · Santeri Pakola, Dafne C. A. Quixabeira, et al. · Frontiers in Immunology · 7
Clean and folded: Production of active, high quality recombinant human interferon-λ1
2021 · Aram Shaldzhyan, Yana Zabrodskaya, et al. · Process Biochemistry · 7
PDF
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
2025 · Santeri A. Pakola, Nea Ojala, et al. · Cancer Immunology Immunotherapy · 6
PDF
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
2025 · Tatiana V. Kudling, Dmitrii Bychkov, et al. · Cancer Gene Therapy · 6
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma
2025 · Victor Arias, Tatiana V. Kudling, et al. · Molecular Therapy Oncology · 5
Epitope specificity of two anti‐morphine monoclonal antibodies: In vitro and in silico studies
2020 · Alexander V. Trofimov, Alexey V. Sokolov, et al. · Journal of Molecular Recognition · 3
Works count: 74
Citation count: 480
H-index: 13
I10-index: 17
Year
Topic
Type